Tumor rat sarcoma gene (RAS) status is a negative anti-epidermal growth factor receptor therapy biomarker in metastatic colorectal cancer (mCRC). Early tumor shrinkage (ETS) and depth of response (DpR) were evaluated for 270 patients with RAS wild type mCRC randomized to best supportive care with or without panitumumab (6.0 mg/kg, intravenously, on day 1 of 14-day cycles). Panitumumab improved outcomes, and ETS and DpR might be useful efficacy markers. Introduction: Tumor rat sarcoma gene (RAS) status is a negative predictive biomarker for anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC). We analyzed outcomes according to RAS and v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutational status, and evaluated early tumor shrinkage (ETS) and depth of response (DpR) for patients with wild type RAS. Patients and Methods: Patients with confirmed metastatic colon or rectum adenocarcinoma, wild type Kristen rat sarcoma gene tumor exon 2 status, clinical/radiologic disease progression or toxicity during irinotecan or oxaliplatin treatment, and no previous anti-EGFR therapy were randomized 1:1 to receive best supportive care (BSC) with or without panitumumab (6.0 mg/ kg, intravenously, on day 1 of each 14-day cycle) in this open-label, multicenter, phase III study (20100007). RAS and BRAF mutation status were determined using Sanger sequencing. ETS was evaluated as maximum percentage change from baseline to week 8; DpR was calculated as the percentage change for tumor shrinkage at nadir versus baseline. Results: Overall, 270 patients had RAS wild type mCRC (panitumumab with BSC, n ¼ 142; BSC, n ¼ 128). For patients with wild type RAS tumors, median overall survival (OS; hazard ratio [HR], 0.72; P ¼ .015) and progression-free survival (PFS; HR, 0.45; P < .0001) were improved with panitumumab with BSC versus BSC. Similar improvements were seen for patients with wild type RAS, and wild type BRAF tumors (OS: HR, 0.75; P ¼ .04; PFS: HR, 0.45; P < .0001). Median DpR was 16.9% for the evaluable panitumumab with BSC wild type RAS population. Overall, 69.5% experienced any type of tumor shrinkage at week 8; 38.2% experienced ! 20% shrinkage. Similar improvements in OS and PFS were seen with stratification according to ETS. Conclusion: This analysis showed that panitumumab improved outcomes in wild type RAS mCRC and indicated that ETS and DpR could be used as additional efficacy markers.
Introduction
Panitumumab is a fully human anti-epidermal growth factor receptor (EGFR) antibody that is effective as a monotherapy and in combination with chemotherapy for RAS wild type metastatic colorectal cancer (mCRC). [1] [2] [3] Tumor RAS status has been established as a negative predictive biomarker for anti-EGFR therapy in mCRC in combination with chemotherapy in retrospective analyses as well as a monotherapy in the prospective primary analysis of the 20100007 study. 1, 2, 4, 5 The 20100007 primary analysis showed panitumumab with best supportive care (BSC) versus BSC alone yielded better outcomes in wild type RAS tumors than in wild type Kristen rat sarcoma gene (KRAS) exon 2 mCRC. Significant clinical improvement was seen across all key end points: overall survival (OS), progressionfree survival (PFS), and objective response rate (ORR). 4 Although RAS status is predictive for clinical response, additional biomarkers that further characterize the population that will benefit from anti-EGFR treatment would be of significant value. There has been longstanding interest in v-Raf murine sarcoma viral oncogene homolog B (BRAF) as a potential mCRC biomarker, 6 and to date, BRAF mutational status has been shown to be associated with poor outcomes (ie, prognostic). 1, 2, 7 There is little support from randomized studies for BRAF as a predictive biomarker during panitumumab therapy; however, the predictive value of BRAF has been difficult to evaluate because evidence is limited by the poor overall outcomes that patients typically experience. In addition to biomarker identification, novel clinical evaluations might provide further information on the characteristics of response during anti-EGFR therapy. Although tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST) 8 is a standard and important oncology end point, it does not fully consider duration, depth, or timing of response. Thus, complementary end points such as early tumor shrinkage (ETS; tumor shrinkage at or below a specified threshold within a short period of time after treatment initiation) and depth of response (DpR; maximum tumor shrinkage observed) have been evaluated. ETS might be predictive of survival, indicative of sensitivity to therapy and potential to achieve a response. 9 Additionally, it might improve or delay symptoms or even allow for resection 10 and has been associated with improved OS. [9] [10] [11] Similarly, DpR might be associated with longer disease and/or symptom control 9 and has also been associated with improved OS. 9, 11 Limited data on these end points in clinical trials with anti-EGFR inhibitors as monotherapy are available; therefore, we sought to evaluate these end points using data from the 20100007 study.
We report the final analysis results from the 20100007 trial (ClinicalTrials.gov registration NCT01412957), a prospective, openlabel, randomized, phase III trial. Survival outcomes were analyzed according to RAS and BRAF mutational status, and ETS and DpR analyses were evaluated for patients with wild type RAS tumors.
Patients and Methods

Study Design and Patients
Detailed information regarding patient eligibility criteria and study design has been previously reported. 4 Briefly, eligible patients had histologically or cytologically confirmed diagnosis of adenocarcinoma of the colon or rectum and metastatic disease, wild type KRAS tumor exon 2 status assessed centrally, clinical/radiologic disease progression (assessed by investigator in each study center), or toxicity during irinotecan or oxaliplatin treatment, and no previous anti-EGFR therapy. The study protocol was approved by an independent ethics committee at each study center and is available online (see Appendix A in the online version); all patients provided written informed consent.
Treatment
Patients were randomly assigned (1:1) to receive panitumumab (6.0 mg/kg) intravenously on day 1 of each 14-day cycle with BSC (as previously defined 4 ) or BSC alone. Randomization was stratified according to geography (Europe vs. Asia vs. rest of the world) and Eastern Cooperative Oncology Group performance status (0 or 1 vs. 2). Study treatment continued until disease progression, consent withdrawal, or panitumumab intolerance (panitumumab with BSC arm only). On-study crossover from BSC to panitumumab with BSC was prohibited.
Mutational Analysis of KRAS, RAS, and BRAF
Patient tumor samples were screened for mutations in KRAS exon 2 and in codons 12 and 13 to determine study eligibility and for extended RAS analyses as previously described. 4 Analyses of KRAS exons 3 (codons 59 and 61) and 4 (codons 117 and 146), and Neuroblastoma rat sarcoma gene (NRAS) exons 2 (codons 12 and 13), 3 (codons 59 and 61), and 4 (codons 117 and 146) were prespecified in the study protocol and statistical analysis plan. The covariate BRAF exon 15 was also prespecified in the study protocol but was evaluated in an exploratory analysis. RAS and BRAF mutation status were determined by a single central laboratory using bidirectional Sanger sequencing (limit of detection, 5%-25%); RAS mutation status was determined before the primary analysis; BRAF mutation status was determined after the primary analysis was conducted. For time to event end points, hazard ratios (HRs) and 95% confidence intervals (CIs) for panitumumab with BSC relative to BSC alone were estimated from a Cox model, stratified according to the randomization factors, and evaluated using the KaplaneMeier method. Two ETS cutoff values (20% and 0%) were used to evaluate the potential association of ETS with OS and PFS. Descriptive statistics were calculated for DpR. The prognostic relevance of BRAF for OS and PFS was assessed using a Cox model HR (BRAF wild type vs. BRAF mutant). For objective response, the common odds ratio (OR) across strata of randomization factors and exact 95% CIs were calculated. For the final analysis, no hypothesis was formally tested; all P values are descriptive.
Results
Patients
Overall, 377 patients with wild type KRAS exon 2 tumors were included in the intent-to-treat analysis; 270 patients had RAS wild 
Final Analysis of Panitumumab D BSC in Chemorefractory mCRC
-Clinical Colorectal Cancer September 2018
type mCRC (panitumumab with BSC, n ¼ 142; BSC, n ¼ 128; Figure 1 ). Baseline demographic and clinical characteristics of the wild type RAS population are presented in Appendix B, Supplemental Months   0  2  4  6  8  10  12  14  16  18  20  22  24  26  28  30  32  34   142  133  119  104  92  71  54  45  39  27  22  20  15  8  5  5  2  0   128  101  78  59  46  42  32  24  20  15  13  11  11  5  3 Figure 2A , Table 1 ). In analyses of patient subgroups defined according to baseline characteristics, OS generally favored panitumumab with BSC versus BSC alone (see Appendix B, Supplemental Figure B .1 in the online version). PFS was improved among patients in the panitumumab arm versus those in the BSCalone arm. Median PFS was 5.2 (95% CI, 3.5-5.3) months in the panitumumab with BSC arm versus 1.7 (95% CI, 1.6-2.2) months in the BSC arm (HR, 0.45; 95% CI, 0.35-0.59, P < .0001; Figure 2B , Table 1 ).
Patients in the panitumumab with BSC arm had an ORR of 31.0% versus 2.3% in patients in the BSC arm (OR, 20.0; 95% CI, 5.9-101.6; P < .0001); no patient in either arm had a complete response. In the panitumumab with BSC arm for patients who had response (n ¼ 44), median time to response was 1.61 (interquartile range
Efficacy in the Wild Type RAS Population With BRAF Mutations
In patients with wild type RAS, wild type BRAF tumors, median OS was 10.2 (95% CI, 8.7-11.7) months in the panitumumab with BSC arm (n ¼ 128) versus 7.4 (95% CI, 5.7-10.0) months in the BSC arm (n ¼ 114; HR, 0.75; 95% CI, 0.57-0.99; P ¼ .04). Median PFS was 5.3 (95% CI, 3.6-5.4) months in the panitumumab with BSC arm versus 1.8 (95% CI, 1.6-2.6) months in the BSC arm (HR, 0.45; 95% CI, 0.34-0.60; P < .0001). In patients with wild type RAS, mutant BRAF tumors, median OS was 4.1 (95% CI, 3.8-13.9) months in the panitumumab with BSC arm (n ¼ 9) versus 3.0 (95% CI, 1.3-4.1) months in the BSC arm (n ¼ 11; HR, 0.39; 95% CI, 0.10-1.51; P ¼ .16). Median PFS was 1.5 (95% CI, 0.8-3.7) months in the panitumumab with BSC arm versus 1.3 (95% CI, 0.9-1.8) months in the BSC arm (HR, 0.28; 95% CI, 0.07-1.08; P ¼ .05; Table 1 ). Among patients with wild type RAS (n ¼ 270), few patients with BRAF-mutant tumors (n ¼ 20) were identified. BRAF mutations were associated with poor prognosis for OS (HR, 0.33 [wild type BRAF to mutant BRAF in the BSC arm]; 95% CI, 0.17-0.66; Figure 2E ).
For patients with wild type RAS, wild type BRAF tumors, those in the panitumumab with BSC arm (n ¼ 128) had an ORR of 33.6% versus 2.6% in patients in the BSC arm (n ¼ 114; OR, 20.5; 95% CI, 5.9-102.9; P < .0001). For patients with wild type RAS, mutant BRAF tumors, those in the panitumumab with BSC arm (n ¼ 9) had an ORR of 11.1% versus 0% in patients in the BSC arm (n ¼ 11; OR, not estimable; 95% CI, 0.06 to not estimable; P ¼ .91).
Depth of Response and ETS in the Wild Type RAS Population
In the panitumumab with BSC arm of the wild type RAS population evaluable for DpR (n ¼ 130), median DpR was 16.9% (IQR, 0%-37.5%). The maximum percentage reduction of target lesions per patient is shown in Figure 3 ; 97 patients (68%) had some degree of reduction in lesion dimensions at any point during the study.
Because ETS has previously been associated with improved survival in combination therapy studies, 10, 12 we evaluated ETS in this monotherapy study. The percent change in target lesions from baseline to nadir at week 4 or week 8 was analyzed (n ¼ 131). Overall, 69.5%(n ¼ 91) of patients experienced any type of tumor shrinkage at week 8, and 38.2%(n ¼ 50) experienced ! 20% tumor shrinkage. When patients were stratified according to ETS ! 20% or < 20%, those with ETS ! 20% (n ¼ 50) had a median OS of 13.6 (95% CI, 10.5-16.9) months and those with ETS < 20% (n ¼ 81) had a median OS of 8.5 (95% CI, 7.1-10.6) months (HR, 0.58; 95% CI, 0.40-0.85; P ¼ .005; Table 2 , Figure 2C ). Similarly, median PFS was 5.4 (95% CI, 5.3-7.1) months and 3.5 (95% CI, 2.7-5.3) months, respectively (HR, 0.57; 95% CI, 0.40-0.82; P ¼ .002; Figure 2D ). When stratified with a threshold of ETS ! 0% (n ¼ 91) versus < 0% (n ¼ 40), median OS was 11.5 (95% CI, 10.0-13.7) months and 6.1 (95% CI, 4.0-10.6) months, respectively (HR, 0.62; 95% CI, 0.42- 
Safety
In the wild type RAS population, 97.2% of those who received panitumumab with BSC (n ¼ 142) and 61.7% of those who received BSC alone (n ¼ 128) experienced an AE of any grade (see Appendix B, Supplemental Table B .4 in the online version). The most common AEs of any grade occurring in ! 20% of patients in either treatment arm were rash (39.4%; 0.8%), hypomagnesemia (31.0%; 0.8%), dermatitis acneiform (28.2%; 0%), and pruritus (24.6%; 0%). The incidences of Grade 3 and 4 AEs were 39.4% and 7.0%, respectively, for panitumumab with BSC and 15.6% and 3.1% for BSC alone. Grade 3/4 AEs with ! 5% incidence in either treatment arm were rash (7.7%; 0%), hypomagnesemia (7.0%; 0%), dermatitis acneiform (6.3%; 0%), and abdominal pain (2.1%; 6.3%). In the wild type RAS population, 5 patients (3.5%) in the panitumumab with BSC arm discontinued treatment because of AEs versus 2 patients (1.6%) in the BSC arm. The incidence of infusion reactions in the panitumumab with BSC arm was 1.4% (n ¼ 2).
Discussion
In this follow-up final analysis, efficacy findings for patients with wild type RAS tumors presented in the primary analysis 4 were confirmed without any significant changes. Additionally, median OS for patients with the wild type KRAS exon 2 (10.0 months) as well as wild type RAS (10.0 months) mCRC treated with panitumumab with BSC was also consistent with other previously reported studies. [13] [14] [15] Toxicities were consistent with other 
Overall Survival
Median (95% CI), months 13.6 (10.5-16.9) 8.5 (7.1-10.6) 11.5 (10.0-13.7) 6.1 (4.0-10. 
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panitumumab monotherapy studies; no new safety signals were identified. Previous studies indicated BRAF mutations do not appear to be negative predictive markers of response to panitumumab, although they might be associated with poor prognosis. 1, 2, 16 Consistent with these studies, 1,2,16 BRAF mutations in 20100007 appeared to be negatively prognostic for OS but did not indicate that benefit could not be achieved with anti-EGFR therapy. Although the duration of PFS observed in patients with wild type RAS/mutant BRAF tumors was modest with panitumumab with BSC as well as BSC alone, the OS HR still favored the panitumumab with BSC arm versus BSC alone. However, because of the short OS duration observed among patients with BRAF mutations, the absolute magnitude of this benefit was small (1.1 months). These results must be interpreted with caution because of the small sample size of the BRAF mutant subgroup, consistent with other studies. 1, 2 Overall, fewer patients with BRAF mutations were observed in this study (5%) versus earlier treatment lines (5%-15%), 1,2 potentially because BRAF-mutant patients have poor prognosis, and many might have died before reaching the third-line setting. This might have possibly resulted in a surviving subset of patients with BRAF mutations who differed clinically and biologically from those enrolled in first-line studies.
In this study, median DpR was 16.9%, with approximately 68% of the panitumumab with BSC arm achieving some degree of reduction in tumor lesion size. Previous studies have shown improved DpR in the first-line setting with EGFR inhibitors in combination with chemotherapy versus bevacizumab with chemotherapy. 9, 12, 17 The number of patients with some degree of reduction in tumor dimensions in this study (> 60%) was comparable with previously reported percentages, 9,12,17 despite having previous exposure to multiple agents. Moreover, in this study, the wild type RAS population had a median DpR of 16.9% (IQR, 0%-37.5%; range, 0-100). Because the ORR was 31.0% in the panitumumab with BSC arm, it is clear that many patients had a reduction in tumor burden but did not meet the requirement for a 30% reduction in tumor dimensions and/ or requirement for confirmation of response stipulated in RECIST version 1.1. 8 Notwithstanding this failure to achieve an objective response per RECIST version 1.1, patients with a reduction in tumor lesion dimensions < 30% clearly derive some measure of benefit from anti-EGFR therapy. These results illustrate that although RECIST is an important objective measure of clinical outcome, there are clinically meaningful changes in tumor dimensions that are not captured. Panitumumab monotherapy also resulted in ETS. In this analysis of the clinical utility (non-RECIST) of panitumumab, 38.2% of patients had ETS ! 20%; this level of tumor shrinkage shortly after treatment initiation represents a clinically meaningful component of treatment (eg, time to response) not captured by RECIST, and might be very interesting for patients with complaints who derive fast alleviation of tumor symptoms after treatment initiation. Importantly, patients in this study treated with panitumumab with BSC with ETS ! 20% had longer OS (13.6 months) versus patients with ETS < 20% (8.5 months). Similar associations between ETS and OS were observed in previous combination studies (ie, PRIME and PEAK). 10, 12 In the phase III PRIME trial, more patients receiving panitumumab with oxaliplatin, fluorouracil, and leucovorin 4 versus oxaliplatin, fluorouracil, and leucovorin 4 alone had ETS ! 20% (72% vs. 57%; P < .001) at week 8, which correlated with improved OS (32.5 vs. 12.6 months). 10 In the phase II PEAK trial, panitumumab with modified fluorouracil, leucovorin, and oxaliplatin 6 was associated with a higher rate of ETS (! 30%) versus bevacizumab with modified fluorouracil, leucovorin, and oxaliplatin 6 (64% vs. 45%; P ¼ .02) and also correlated with improved survival. 12 More- 18 Together, these results indicate that ETS, even in the refractory setting, appears to be associated with survival benefit and could possibly be used as an additional marker for efficacy, particularly in pretreated patients who receive panitumumab monotherapy. This analysis was limited by the unblinded nature of the study, the number of biomarkers evaluated, and the lack of patient stratification according to tumor localization. Additionally, evaluations were conducted by investigators rather than at a central location, which might have introduced bias.
Conclusion
Consistent with the primary analysis, 4 the final analysis showed panitumumab improved OS and PFS in patients with chemotherapy-refractory wild type KRAS exon 2 and wild type RAS mCRC. Additionally, this study indicated ETS and DpR correlate with improvement in OS and PFS, even in later lines of therapy. Although the number of patients with BRAF mutations was small, results were prognostic for outcomes and consistent with other studies. Additionally, toxicities were similar to other panitumumab monotherapy studies. Panitumumab should be considered in combination or as monotherapy for effect on survival as well as for the potential for tumor shrinkage. Overall, these results further validate RAS as a predictive biomarker for anti-EGFR therapies, substantiate the importance of RAS testing at diagnosis, and indicate ETS might be a clinically useful end point for combination treatment because it was an effective predictor of monotherapy response.
Clinical Practice Points
Tumor RAS status has been established as a negative predictive biomarker for anti-EGFR therapy in mCRC. This study further validates RAS as a predictive biomarker for anti-EGFR therapies, underscoring the importance of RAS testing at diagnosis, and indicating that ETS might be a clinically useful end point to inform future combination treatment because it was an effective predictor of response to monotherapy.
